A month after Sutro closed an $85.4m series E round backed by Merck & Co, Celgene, Amgen and Eli Lilly, the cancer drug developer has filed for a $75m initial public offering.
Sutro Biopharma, a US-based cancer drug developer backed by pharmaceutical firms Amgen, Celgene, Eli Lilly and Merck & Co, filed for a $75m initial public offering on the Nasdaq Global Market on Wednesday.
Founded in 2003 as Fundamental Applied Biology, Sutro Biopharma is creating immuno-onology treatments, antibody drug conjugates and bispecific antibodies aimed at cancer and autoimmune diseases.
The company’s drug discovery platform, XpressCF, is based on research by founder James Swartz, the James H. Clark professor in the…
